NEW YORK (GenomeWeb News) – Diagenic recently announced a 10-for-1 reverse stock split, which took effect on May 30.
As a result of the split, each share of the company's stock was bumped up to NOK.50 ($.09) from NOK.05. After the split, the Norwegian firm had about 27 million shares of common stock outstanding.
The company develops diagnostic tests that measure disease-specific gene expression signatures in biofluids. It currently has two tests on the market, one for Alzheimer's disease and another for breast cancer.